Structure Therapeutics Announces Aleniglipron Clinical Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 16 2026
0mins
Should l Buy GPCR?
Structure Therapeutics announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity. This includes 44-week data from the Phase 2 ACCESS II study and interim data from the ongoing body composition study and the ACCESS open label extension study. Aleniglipron is an investigational orally-available, once-daily, nonpeptide small molecule agonist of the glucagon-like-peptide-1 receptor designed to address patient needs and accessibility. In the Phase 2 ACCESS II study, aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% at the 180 mg dose and 16.0% at the 240 mg dose at 44 weeks. In the ACCESS OLE study, aleniglipron achieved continued weight loss from 36 weeks, up to 16.2% with 120 mg at 56 weeks. Both studies continue to demonstrate no evidence of weight loss plateau. Aleniglipron continues to demonstrate a tolerability profile that is consistent with the GLP-1 receptor agonist class and a compelling safety profile with no off-target events. In ACCESS II, across all active arms in participants who reached doses 120 mg or higher from 28 to 44 weeks, there was only one adverse event-related treatment discontinuation. With a median follow-up of 20 weeks, the tolerability data as of the February 20, 2026 cutoff date from the interim analyses of the OLE and the body composition studies provide further support that the use of 2.5 mg as a lower starting dose very meaningfully reduces the rate of AE-related discontinuations during the titration phase. In the OLE, with a median follow-up of 20 weeks, there was an overall AE-related discontinuation rate of 2%. In the body composition study, with a median follow-up of 20 weeks, there was an overall AE-related discontinuation rate of 3.4% in the aleniglipron arm. Together, these positive efficacy, tolerability and safety findings continue to support the advancement of aleniglipron into Phase 3 clinical development, with initiation anticipated in the second half of 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GPCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GPCR
Wall Street analysts forecast GPCR stock price to rise
15 Analyst Rating
15 Buy
0 Hold
0 Sell
Strong Buy
Current: 45.920
Low
65.00
Averages
106.50
High
140.00
Current: 45.920
Low
65.00
Averages
106.50
High
140.00
About GPCR
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Viking and Structure Intensify Competition in Obesity Drug Development
- Clinical Trial Progress: Viking announced the enrollment of approximately 1,000 patients with obesity or overweight type 2 diabetes in the late-stage trial of VK2735, with a primary endpoint assessing weight change after 78 weeks, which could significantly enhance its market competitiveness if successful.
- Significant Drug Efficacy: In a mid-stage trial, VK2735 achieved a mean weight loss of 14.7% in 13 weeks, establishing a solid foundation for its subsequent clinical development and potentially attracting more investor interest.
- Market Potential: According to Koyfin, GPCR stock has a 12-month target of $109, implying a 147.95% upside, while VKTX's target is $92.72, representing a 209.80% upside, indicating strong prospects for both companies in the obesity drug market.
- Investor Sentiment Shift: While VKTX stock has risen 24% this year, GPCR has surged 154%, reflecting differing market perceptions, with VKTX sentiment remaining neutral and GPCR appearing more bearish.
See More
B Group Initiates Position in Structure Therapeutics
- New Position Disclosure: B Group disclosed a new position in Structure Therapeutics by acquiring 90,000 shares in Q4 2025, amounting to $6.26 million, reflecting confidence in the company's drug development potential, particularly in chronic disease treatments.
- Asset Allocation Impact: This new stake represents 4.62% of B Group's reportable U.S. equity assets, indicating a strategic focus on the biopharmaceutical sector that may attract further investor interest in its future performance.
- Strong Market Performance: As of last Friday, Structure Therapeutics shares were priced at $48.59, marking a staggering 132% increase over the past year, significantly outperforming the S&P 500's 15% rise, showcasing strong market demand for its products and investor confidence.
- R&D Challenges and Opportunities: Despite posting a net loss of $141 million for 2025 and increased R&D spending, the lead drug candidate's mid-stage trial showed over 16% weight loss, indicating competitive strength in the obesity and metabolic disease market, with future clinical execution being crucial.
See More
B Group Acquires Shares in Structure Therapeutics
- New Investment Disclosure: On February 17, 2026, B Group disclosed to the SEC that it acquired 90,000 shares of Structure Therapeutics in the fourth quarter, indicating a continued interest in the biotechnology sector.
- Value Growth: As of December 31, 2025, B Group's stake in Structure Therapeutics was valued at $6.26 million, representing 4.62% of its 13F assets, which, while not in the top five holdings, still reflects confidence in the company.
- Market Potential Analysis: Structure Therapeutics focuses on developing innovative oral small molecule drugs for chronic diseases, with its lead candidate GSBR-1290 achieving over 16% weight loss in mid-stage trials, showcasing its competitiveness in the obesity and metabolic disease market.
- Financial Condition Consideration: Despite posting a net loss of approximately $141 million last year and a 28% drop in stock price this year, Structure Therapeutics' long-term growth potential hinges on clinical execution, necessitating investor attention on its R&D progress.
See More
Novo Nordisk's High-Dose Wegovy Approved by FDA
- High-Dose Approval: The FDA has approved Novo Nordisk's high-dose Wegovy at 7.2 mg, set to launch in April, aiming to regain market share against Eli Lilly's Zepbound.
- Clinical Trial Results: In a phase three trial, high-dose Wegovy led to an average weight loss of 20.7% over 72 weeks, significantly outperforming the standard dose's 15%, enhancing its competitive edge.
- Increased Patient Options: The new dosage provides more options for patients who struggle to meet weight loss targets, as noted by Novo Nordisk's U.S. medical head, potentially improving treatment satisfaction and outcomes.
- Policy Support: This approval marks the first GLP-1 treatment under the FDA's new national priority voucher plan, aimed at expediting drug review times, highlighting Novo Nordisk's strategic positioning in the industry.
See More
Structure Therapeutics Reports Promising Phase 2 Data for Obesity Drug
- Clinical Trial Results: Structure Therapeutics reported significant weight loss of 16.3% and 16% at 180 mg and 240 mg doses respectively in the ACCESS II study, highlighting the potential of aleniglipron in obesity treatment and opening new market opportunities for the company.
- Sustained Weight Loss: In the open-label extension study, aleniglipron achieved a continued weight loss of 16.2% at the 120 mg dose over 56 weeks without a weight loss plateau, indicating long-term efficacy and enhancing its competitive edge in the market.
- Future Development Plans: The company anticipates moving into phase 3 clinical trials in the second half of the year, paving the way for potential product launch, which could attract more investor interest and boost stock performance.
- Positive Market Reaction: Following the release of promising clinical data, Structure Therapeutics' stock rose approximately 8% in Monday trading, reflecting market optimism regarding the prospects of its obesity treatment drug and potentially strengthening the company's position in the biopharmaceutical sector.
See More
Casdin Capital Reduces Stake in Structure Therapeutics
- Stake Reduction Transaction: According to a February 17, 2026 SEC filing, Casdin Capital sold 380,000 shares of Structure Therapeutics in Q4, an estimated $15.52 million trade that reflects a cautious outlook on the company's future performance.
- Change in Holdings Proportion: Following this sale, Structure Therapeutics accounted for only 5.08% of Casdin's 13F assets, indicating a reallocation of the investment portfolio that may impact the company's future liquidity.
- Market Performance Analysis: As of February 17, 2026, GPCR shares were priced at $71.41, reflecting a 214.3% increase over the past year, significantly outperforming the S&P 500 by 180.87 percentage points, indicating strong market confidence in its potential products.
- Financial Overview: Despite ending 2025 with $1.4 billion in cash and investments sufficient to fund operations through 2028, the company reported a net loss of $141.2 million, highlighting the financial strain from high R&D expenditures during its clinical stage.
See More
Viking and Structure Intensify Competition in Obesity Drug Development
- Clinical Trial Progress: Viking announced the enrollment of approximately 1,000 patients with obesity or overweight type 2 diabetes in the late-stage trial of VK2735, with a primary endpoint assessing weight change after 78 weeks, which could significantly enhance its market competitiveness if successful.
- Significant Drug Efficacy: In a mid-stage trial, VK2735 achieved a mean weight loss of 14.7% in 13 weeks, establishing a solid foundation for its subsequent clinical development and potentially attracting more investor interest.
- Market Potential: According to Koyfin, GPCR stock has a 12-month target of $109, implying a 147.95% upside, while VKTX's target is $92.72, representing a 209.80% upside, indicating strong prospects for both companies in the obesity drug market.
- Investor Sentiment Shift: While VKTX stock has risen 24% this year, GPCR has surged 154%, reflecting differing market perceptions, with VKTX sentiment remaining neutral and GPCR appearing more bearish.
See More
B Group Initiates Position in Structure Therapeutics
- New Position Disclosure: B Group disclosed a new position in Structure Therapeutics by acquiring 90,000 shares in Q4 2025, amounting to $6.26 million, reflecting confidence in the company's drug development potential, particularly in chronic disease treatments.
- Asset Allocation Impact: This new stake represents 4.62% of B Group's reportable U.S. equity assets, indicating a strategic focus on the biopharmaceutical sector that may attract further investor interest in its future performance.
- Strong Market Performance: As of last Friday, Structure Therapeutics shares were priced at $48.59, marking a staggering 132% increase over the past year, significantly outperforming the S&P 500's 15% rise, showcasing strong market demand for its products and investor confidence.
- R&D Challenges and Opportunities: Despite posting a net loss of $141 million for 2025 and increased R&D spending, the lead drug candidate's mid-stage trial showed over 16% weight loss, indicating competitive strength in the obesity and metabolic disease market, with future clinical execution being crucial.
See More
B Group Acquires Shares in Structure Therapeutics
- New Investment Disclosure: On February 17, 2026, B Group disclosed to the SEC that it acquired 90,000 shares of Structure Therapeutics in the fourth quarter, indicating a continued interest in the biotechnology sector.
- Value Growth: As of December 31, 2025, B Group's stake in Structure Therapeutics was valued at $6.26 million, representing 4.62% of its 13F assets, which, while not in the top five holdings, still reflects confidence in the company.
- Market Potential Analysis: Structure Therapeutics focuses on developing innovative oral small molecule drugs for chronic diseases, with its lead candidate GSBR-1290 achieving over 16% weight loss in mid-stage trials, showcasing its competitiveness in the obesity and metabolic disease market.
- Financial Condition Consideration: Despite posting a net loss of approximately $141 million last year and a 28% drop in stock price this year, Structure Therapeutics' long-term growth potential hinges on clinical execution, necessitating investor attention on its R&D progress.
See More
Novo Nordisk's High-Dose Wegovy Approved by FDA
- High-Dose Approval: The FDA has approved Novo Nordisk's high-dose Wegovy at 7.2 mg, set to launch in April, aiming to regain market share against Eli Lilly's Zepbound.
- Clinical Trial Results: In a phase three trial, high-dose Wegovy led to an average weight loss of 20.7% over 72 weeks, significantly outperforming the standard dose's 15%, enhancing its competitive edge.
- Increased Patient Options: The new dosage provides more options for patients who struggle to meet weight loss targets, as noted by Novo Nordisk's U.S. medical head, potentially improving treatment satisfaction and outcomes.
- Policy Support: This approval marks the first GLP-1 treatment under the FDA's new national priority voucher plan, aimed at expediting drug review times, highlighting Novo Nordisk's strategic positioning in the industry.
See More
Structure Therapeutics Reports Promising Phase 2 Data for Obesity Drug
- Clinical Trial Results: Structure Therapeutics reported significant weight loss of 16.3% and 16% at 180 mg and 240 mg doses respectively in the ACCESS II study, highlighting the potential of aleniglipron in obesity treatment and opening new market opportunities for the company.
- Sustained Weight Loss: In the open-label extension study, aleniglipron achieved a continued weight loss of 16.2% at the 120 mg dose over 56 weeks without a weight loss plateau, indicating long-term efficacy and enhancing its competitive edge in the market.
- Future Development Plans: The company anticipates moving into phase 3 clinical trials in the second half of the year, paving the way for potential product launch, which could attract more investor interest and boost stock performance.
- Positive Market Reaction: Following the release of promising clinical data, Structure Therapeutics' stock rose approximately 8% in Monday trading, reflecting market optimism regarding the prospects of its obesity treatment drug and potentially strengthening the company's position in the biopharmaceutical sector.
See More
Casdin Capital Reduces Stake in Structure Therapeutics
- Stake Reduction Transaction: According to a February 17, 2026 SEC filing, Casdin Capital sold 380,000 shares of Structure Therapeutics in Q4, an estimated $15.52 million trade that reflects a cautious outlook on the company's future performance.
- Change in Holdings Proportion: Following this sale, Structure Therapeutics accounted for only 5.08% of Casdin's 13F assets, indicating a reallocation of the investment portfolio that may impact the company's future liquidity.
- Market Performance Analysis: As of February 17, 2026, GPCR shares were priced at $71.41, reflecting a 214.3% increase over the past year, significantly outperforming the S&P 500 by 180.87 percentage points, indicating strong market confidence in its potential products.
- Financial Overview: Despite ending 2025 with $1.4 billion in cash and investments sufficient to fund operations through 2028, the company reported a net loss of $141.2 million, highlighting the financial strain from high R&D expenditures during its clinical stage.
See More
